The Role of Macrolides in Childhood Non-Cystic Fibrosis-Related Bronchiectasis

Table 2

A summary of clinical trials of the use of macrolide therapy in bronchiectasis.

Author	Year	Study drug	Study design	Age group	Benefit
Tsang et al. [58]	1999	Erythromycin	RDBPCT	Adult	↑ FEV1, ↑  FVC; ↓ sputum volume
Yalcin et al. [28]	2006	Clarithromycin	RPCT	Paediatric	↓  sputum volume,; ↓ sputum cytokines
Koh et al. [59]	1997	Roxithromycin	RDBPCT	Adult	↓ airway reactivity to methacholine
Davies and Wilson [60]	2004	Azithromycin	Prospective open-label	Adult	↓ symptoms and; ↑ DLCO
Cymbala et al. [57]	2005	Clarithromycin	Randomised open-label, crossover	Adult	↓ sputum volume
Serisier and Martin [55]	2011	Erythromycin	Retrospective RCT	Adult	↓  exacerbations; ↓ antibiotic use
Coeman et al. [61]	2011	Erythromycin	Retrospective observational	Adult	Improved symptom score
Anwar et al. [56]	2008	Azithromycin	Retrospective observational	Adult	↑  FEV1; ↓  exacerbations

Abbreviations: ↑, increased, ↓, decreased; D_LCO, pulmonary diffusion capacity for carbon monoxide; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; RCT, randomised controlled trial; RDBCT, randomised double-blind controlled trial; RDBPCT, randomised double-blind placebo-controlled trial.